An unnamed biopharma sponsor filed a citizen petition asking the FDA to change its approach to publicly releasing complete response letters (CRLs), arguing the disclosure process is unlawful and raises intellectual property concerns. The petition targets the FDA’s “radical transparency” initiative that made more than 200 CRLs public in 2025, now expanded to more than 300 letters, and also asks for a defined contestation window before publication. The request argues the agency should notify sponsors in advance and allow them to respond within 10 days, or at minimum provide written reasoning if publication proceeds despite objections. The dispute lands as investors have generally viewed the CRL posting policy positively for accountability—setting up a direct clash between market transparency and proprietary data protections.